



## December Big Mover Biotech Stocks To Watch

Brought to you by [BiopharmIQ](#), your personal biotech stock research companion

*\*This report was updated 11/22/22 - try BPIQ for free to see the fully updated report as readouts occur.\**

### Summary

- Every month we identify biotech Big-Mover stocks to watch with key upcoming clinical trial readouts.
- Our initial December Biotech Stocks to Watch (Big Movers and Suspected Movers) includes 32 companies (See Tables 1A and 1B).
- The December Big-Mover catalyst events are mostly Phase 2 or 3 readouts & PDUFAs
- The December Big-Mover catalyst events include 2 PDUFAs and the December Suspected Mover catalyst events include 5 PDUFAs
- See Table 2 for Suspected Movers through the first half of 2023

Tables 1A and 1B provide a list of Big-Mover™ stocks that were identified by our Big-Mover™ analysis as stocks with upcoming catalysts, for which options data indicates it is likely that the stock will move at least 20% if there is a clean catalyst readout, as well as companies with important readouts but which currently do not indicate a big move. These Big-Mover™ stocks have catalyst events expected to read out in December 2022 (Table 1A). Suspected Movers to Watch catalysts appear to be important catalysts based on our initial diligence, but are catalysts for whom the market volatility data does not currently indicate a big move (Table 1B). Both tables are ordered by the highest predicted movement according to stock options data.

Table 1A. Big Mover Events December 2022

Ticker	Catalyst
RXDX	Phase 2 Data readout - PRA023 (Anti-TL1A mAb) - UC & CD
MDGL	Phase 3 Data readout - Resmetirom - NASH
RLMD	Phase 3 Data readout - REL-1017 - MDD

XFOR	Phase 3 Data readout - Mavorixafor - WHIM Syndrome
EIGR	Phase 3 Data readout - Lonafarnib (Ritonavir) - Hepatitis D
AMTI	Phase 2 Data readout - AMT-101 (IL-10 oral agonist) - UC
TGTX	PDUFA Approval decision - Ublituximab (CD20) - MS
AFMD	Phase 2 Data readout - AFM13 - PTCL
MRTX	PDUFA Approval decision - Adagrasib - NSCLC
ATAI	Phase 2a Data readout - PCN-101 - TRD

Table 1B. Suspected Movers to Watch December 2022

<b>Ticker</b>	<b>Catalyst</b>
VRNA	Phase 3 Data readout - Ensifentrine - COPD
MEIP	Phase 2 Data readout - Zandelisib - r/r Follicular Lymphoma
RCUS	Phase 2/3 Data readout - Domvanalimab - NSCLC
ALDX	Phase 2 Data readout - ADX-629 - Alcoholic hepatitis
CHRS	PDUFA Approval decision - Toripalimab + Chemotherapy - Nasopharyngeal carcinoma
AXSM	Phase 3 Data readout - AXS-05 - Alzheimer's disease agitation
CYTK	PDUFA AdComm - Omecamtiv Mecarbil - Heart failure
PTCT	Phase 3 Data readout - PTC923 - PKU
ARQT	Phase 3 Data readout - ARQ-151 topical roflumilast cream - Atopic dermatitis
INSM	Phase 2 Data readout - Brensocatib - Cystic fibrosis
VNDA	Phase 2 Data readout - VQW-765 - Anxiety
VNDA	Phase 3 Data readout - Fanapt® (iloperidone) - Bipolar disorder
CORT	Phase 2 Data readout - Miricorilant - AIWG
IONS	Phase 2 Data readout - Cimdelsin - Acromegaly
IONS	Phase 2b Data readout - IONIS-AGT-LRx - Hypertension & heart failure
AZN	PDUFA Approval decision - LYNPARZA (olaparib) - mCRPC
GILD	PDUFA Approval decision - Lenacapavir - HIV
DRMA	Phase 2 Data readout - DMT310 - Rosacea
IPSEY	PDUFA Approval decision - Palovarotene - FOP
PHVS	Phase 2 Data readout - PHVS416 Hereditary angioedema

RHHBY	PDUFA Approval decision - Lunsumio (Mosunetuzumab) - Follicular lymphoma
SNPX	Phase 2b Data readout - Bryostatin-1 - Alzheimer's disease

Our December Big-Mover stocks to watch list likely includes a number of companies/read-outs that will pique your interest. The list includes two PDUFAs: TGTX with a PDUFA date of 12/28/22 and MRTX with a PDUFA date of 12/14/22. As a reminder, we provided more information regarding this month's PDUFAs in our previously published, December PDUFA forum post ([HERE](#)). The December Suspected Movers to Watch list includes an additional five PDUFA target action dates.

Table 2 shows all currently identified suspected movers through the first quarter of 2023. These include many late stage trial readouts to keep an eye on in the coming months, as many may become Big Movers as the readout dates get closer.

Table 2. Suspected Movers through Q1 2023

<b>Ticker</b>	<b>Asset</b>	<b>Indication</b>	<b>Catalyst</b>	<b>Date</b>
ITCI	Lumateperone	MDD	Phase 3 Data readout	Q1 2023
GERN	Imetelstat (GRN163L)	HMM (Hematologic Myeloid Malignancies) and MDS (Myelodysplastic Syndrome)	Phase 3 Data readout	Early January 2023
GTHX	Trilaciclib (Cosela) (CDK4/6 inhibitor)	CRC (Colorectal Cancer) and Breast Cancer	Phase 3 Data readout	Early Q1 2023
ZYME	Zanidatamab	Biliary tract Cancer	Phase 3 Data readout	Early 2023
CYTK	Omecamtiv Mecarbil	HFrEF (Heart Failure with Reduced Ejection Fraction)	PDUFA	February 28, 2023

	(cardiac myosin activator)			
APTX	NYX-458	Parkinson's Disease	Phase 2 Data readout	Q1 2023
CLVS	Rucaparib	Ovarian cancer	Phase 3 Data readout	Q1 2023
PTCT	Vatiquinone	Mitochondrial Epilepsy	Phase 2/3 Data readout	Q1 2023
ESPR	Nexletol (bempedoic acid)	HeFH	MACE trial outcomes	Q1 2023
SELB	SEL-212 (Pegadricase)	Chronic refractory gout	Phase 3 Data readout	Q1 2023
ETNB	BIO89-100 (FGF21 analog)	NASH (Nonalcoholic steatohepatitis)	Phase 2b/3 Data readout	Q1 2023
ALT	HepTCell	Chronic Hepatitis B	Phase 2 Data readout	H1 2023
ASLN	ASLAN004 (IL-13Ra1 inhibitor)	AD (Atopic Dermatitis)	Phase 2b Data readout	H1 2023
AXSM	AXS-12 (reboxetine) (NE reuptake inhibitor)	Narcolepsy	Phase 3 Data readout	H1 2023
CERE	CVL-871 (D1/D5 partial antagonist)	Dementia-Related Apathy	Phase 2 Data readout	H1 2023
CERE	Tavapadon (adjunct with L-Dopa)	Late Parkinson's	Phase 3 Data readout	H1 2023
GLPG	GLPG2737 (CFTR inhibitor)	ADPKD (Autosomal Dominant Polycystic Kidney Disease)	Phase 2 Data readout	H1 2023
GTHX	Trilaciclib (Cosela) (CDK4/6 inhibitor)	NSCLC (Non-small cell lung cancer)	Phase 2 Data readout	H1 2023

FGEN	Roxadustat	Anemia in MDS (Myelodysplastic syndrome)	Phase 3 Data readout	H1 2023
PLRX	PLN-74809 (Dual selective inhibitor of aVβ6/aVβ1)	Primary Sclerosing Cholangitis	Phase 2a Data readout	H1 2023
SPRB	Tildacerfont	Pediatric Classic Congenital Adrenal Hyperplasia	Phase 3 Data readout	H1 2023
GNFT	Elafibranor	PBC (Primary Biliary Cholangitis)	Phase 3 Data readout	Q2 2023
PTCT	Vatiquinone (PTC743)	FA (Friedreich Ataxia)	Phase 3 Data readout	Q2 2023
AVTE	AV-101	PAH (Pulmonary arterial hypertension)	Phase 2b/3 Data readout	Mid 2023
GLTO	GB0139 (inhaled galectin-3 inhibitor)	IPF (Idiopathic Pulmonary Fibrosis)	Phase 2b/3 Data readout	Mid 2023
GRTS	GRANITE	Solid tumors, MSS-CRC (Microsatellite Stable Colorectal Cancer), GEA (Gastroesophageal cancer), NSCLC (Non-small cell lung cancer)	Phase 2/3 Data readout	Mid 2023
GLYC	Uproleselan (GMI-1271)	R/R AML (Relapsed/Refractory Acute Myeloid Leukemia)	Phase 3 Data readout	Mid 2023

Keep in mind that this analysis identifies stocks likely to move substantially higher OR LOWER. It does not predict whether the readout will be positive or that the stock price will increase. You can use this list to find read-outs that pique your interest, and perform your diligence to try to predict trial success or failure. Furthermore, in addition to the analysis linked above, we likely will publish additional analysis on these events in the coming days/weeks. Plus, keep in mind that we will keep an eye on implied volatility and often add companies to the list if implied volatility shoots up as a readout gets

closer. Thus, we might add other December PDUFA's or readouts to the list, if implied volatility shoots up as an event gets closer. We plan to notify you if any additions or readouts occur, in our weekly subscriber emails.

---

#### LIMITATIONS OF Big-Mover™ ANALYSIS

Please keep in mind that these are predicted moves that are provided for informational purposes only, and are based on a strong positive or negative readout. See Big-Mover™ event FAQs [here](#). They do not predict whether the move/readout will be positive or negative, or a strong readout in either direction. Furthermore, there are further limitations of this information, some of which are set out in our February 2021 Big-Mover™ forum post<sup>1</sup> explaining our Big-Mover™ event analysis. Despite its limitations, the information may be helpful to you as you decide which events to diligence further, and to help provide you more or less confidence in your conclusions regarding the likelihood of a positive outcome and/or the magnitude of stock price effect, for a readout. We continue to refine our Big-Mover™ analysis, which may result in updated and improved analysis in the coming months.

[BPIQ - Big Mover™ catalyst readouts for Jan/early Feb 2021 - Google Docs](#)

This article is NOT investment, tax, or legal advice. Please use this as a starting point for your detailed diligence and consult professional advisers before making investment decisions.

---

If you are serious about investing in biotech stocks BPIQ is the research companion that will take you to the next level.

Save yourself time by accessing our database of over 550 companies, 1,800+ of their drug assets, and tools including: Catalyst Calendar, Big Movers, Company Pipelines, and more!

[Try BPIQ Free Today](#)